Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition

Nature. 2021 Feb;590(7846):486-491. doi: 10.1038/s41586-020-03114-6. Epub 2021 Jan 27.

Abstract

Selective targeting of aneuploid cells is an attractive strategy for cancer treatment1. However, it is unclear whether aneuploidy generates any clinically relevant vulnerabilities in cancer cells. Here we mapped the aneuploidy landscapes of about 1,000 human cancer cell lines, and analysed genetic and chemical perturbation screens2-9 to identify cellular vulnerabilities associated with aneuploidy. We found that aneuploid cancer cells show increased sensitivity to genetic perturbation of core components of the spindle assembly checkpoint (SAC), which ensures the proper segregation of chromosomes during mitosis10. Unexpectedly, we also found that aneuploid cancer cells were less sensitive than diploid cells to short-term exposure to multiple SAC inhibitors. Indeed, aneuploid cancer cells became increasingly sensitive to inhibition of SAC over time. Aneuploid cells exhibited aberrant spindle geometry and dynamics, and kept dividing when the SAC was inhibited, resulting in the accumulation of mitotic defects, and in unstable and less-fit karyotypes. Therefore, although aneuploid cancer cells could overcome inhibition of SAC more readily than diploid cells, their long-term proliferation was jeopardized. We identified a specific mitotic kinesin, KIF18A, whose activity was perturbed in aneuploid cancer cells. Aneuploid cancer cells were particularly vulnerable to depletion of KIF18A, and KIF18A overexpression restored their response to SAC inhibition. Our results identify a therapeutically relevant, synthetic lethal interaction between aneuploidy and the SAC.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abnormal Karyotype / drug effects
  • Aneuploidy*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Chromosome Segregation / drug effects
  • Diploidy
  • Genes, Lethal
  • Humans
  • Kinesins / deficiency
  • Kinesins / genetics
  • Kinesins / metabolism
  • M Phase Cell Cycle Checkpoints / drug effects*
  • Neoplasms / genetics
  • Neoplasms / pathology*
  • Spindle Apparatus / drug effects
  • Synthetic Lethal Mutations / drug effects
  • Synthetic Lethal Mutations / genetics
  • Time Factors

Substances

  • KIF18A protein, human
  • Kinesins